This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (22)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

MAURICE M. BEST, MD; CHARLES H. DUNCAN, MD

Arch Intern Med. 1966;118(2):97-102.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

BOTH clofibrate and dextrothyroxine have been shown to reduce the serum levels of cholesterol^1,2 and triglycerides ^3-5 in man. The clinical significance of these lipid-lowering effects and other possible long-term effects of the compounds remain incompletely understood. The relative importance of the levels of cholesterol as compared to those of triglycerides remains unclear since data from adequate prospective studies are limited in regard to triglycerides.

The mode of action of the two compounds appears to be quite different. Dextrothyroxine is thought to act mainly by increasing the conversion of cholesterol to bile acids and thus hasten its excretion⁶; clofibrate has been shown in the rat to reduce net triglyceride output from the liver ⁷ and also to decrease the rate of cholesterol synthesis in the liver.⁸ It is thus not surprising that their effects differ. We suggested that both compounds effect a reduction in serum cholesterol but that clofibrate had . . . [Full Text PDF of this Article]

Author Affiliations
LOUISVILLE

From the Department of Medicine, University of Louisville School of Medicine, Louisville.

Footnotes
Received for publication Tan 7, 1966; accepted May 11.

Reprint requests to 511 S Floyd St, Louisville 40202 (Dr. Best).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?